Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-03-06

FDA Approved: GRALISE — Supplemental Application (Almatica Pharma LLC)

View source ↗

Summary

FDA approved a supplemental application for Gralise (gabapentin) filed by Almatica Pharma LLC, resulting in a label change for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GRALISE (gabapentin)

Snippet

SUPPL AP for GRALISE (GABAPENTIN)